Rigel Pharmaceuticals, Inc. (RIGL)

NASDAQ: RIGL · USD

$50.6

+0.03 (+0.1%)· Recorded snapshot

Market cap	944.8M
Revenue (ttm)	276.8M
Net income (ttm)	321.9M
EPS (ttm)	$16.5
Shares out	18.7M
P/E (trailing)	3.1x
P/E (forward)	15.8x
Volume	174,206
Beta	1.19

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 276.8M
Net income (ttm): 321.9M
EPS (ttm): $16.5
P/E (trailing): 3.1x
P/E (forward): 15.8x
Market cap: 944.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E15.8

P25 13.4P50 20.2P75 35.7

Trailing P/E3.1

P25 15.4P50 25.8P75 43.5

ROE126.9

P25 -113.8P50 -46.5P75 -0.9

ROIC26

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All RIGL indicators

Market & fundamental data

Available fields

255

Groups with data

Currency

USD

Showing 255 of 255 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001034842
Company name	Rigel Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	766559702
Earnings date	2026-11-10
Earnings time	amc
Employees	174
Employees change	10
Employees growth	6.1%
Enterprise value	$889.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1996
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2000-11-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US7665597024
Last 10-K release date	2026-03-03
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	2024-06-27
Last stock split type	Reverse
Market cap	$944.8M
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$50.58
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	RIGL
U.S. state	California
Website	https://www.rigel.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	12.97x
Average P/E ratio (3Y)	14.07x
Earnings yield	32.52%
EV/Earnings	2.76x
EV/EBIT	10.22x
EV/EBITDA	9.92x
EV/FCF	11.2x
EV/Sales	3.21x
FCF / EV yield	8.93%
FCF yield	8.4%
Forward EV/Sales	2.67x
Forward P/E	15.76x
Forward P/S	2.84x
Graham number	91.87688
Graham upside	81.65%
P/(FCF - SBC) ratio	15x
P/(OCF - SBC) ratio	15x
P/B ratio	2.22x
P/E ratio	3.07x
P/FCF ratio	11.9x
P/OCF ratio	11.9x
P/S ratio	3.41x
Price / tangible book value	2.85x
Price/EBITDA ratio	10.53x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	31.45%
EBITDA margin	32.41%
FCF margin	28.68%
Gross margin	75.61%
Operating margin	31.45%
Pretax margin	30.92%
Profit margin	116.3%
Profit per employee	$1.9M
Profitable quarters	8
Profitable years	2
Revenue per employee	$1.6M
ROA	14.95%
ROA (5Y)	-1.88%
ROCE	20.46%
ROE	126.9%
ROIC	26.03%
ROIC (5Y)	-78.28%
SBC / revenue	5.93%
Tax / revenue	-85.39%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	202.71%
EPS growth (Q)	-73.17%
EPS growth (QoQ)	100%
EPS growth years	3
FCF growth	20.67%
FCF growth (Q)	0.38%
FCF growth (QoQ)	1,024.88%
Gross profit growth	-4.06%
Gross profit growth (Q)	-37.79%
Gross profit growth 3Y	41.66%
Gross profit growth 5Y	24.01%
Net income growth	229.08%
Net income growth (Q)	-71%
Net income growth (QoQ)	99.79%
Net income growth years	3
OCF growth	20.6%
OCF growth (Q)	0.38%
OCF growth (QoQ)	1,024.88%
OCF growth 5Y	228.67%
Operating income growth	-16.77%
Operating income growth (Q)	-61.42%
Revenue growth	3.31%
Revenue growth (Q)	-22.6%
Revenue growth (QoQ)	33.81%
Revenue growth 10Y	22.92%
Revenue growth 3Y	31.71%
Revenue growth 5Y	15.34%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$2.6M
EBIT	$87.1M
EBITDA	$89.7M
EPS	$16.45
FCF per share	$4.25
Financing cash flow	$-22.9M
Free cash flow	$79.4M
Free cash flow minus SBC	$63M
Gross profit	$209.3M
Income taxes	$-236.3M
Investing cash flow	$-49.1M
Net borrowing	$-22.8M
Net cash flow	$7.4M
Net income	$321.9M
Operating cash flow minus SBC	$63M
Operating income	$87.1M
Revenue	$276.8M
Stock-based compensation	$16.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.38
Book value per share	$22.81
Debt / EBITDA	0.44
Debt / equity	0.09
Debt / FCF	0.5
Interest coverage	15
Long-term assets	$335.5M
Long-term liabilities	$58,000
Net cash (debt)	$55.4M
Net cash / market cap	5.86%
Net cash growth	16.99%
Net debt / EBITDA	-0.62
Net debt / equity	-0.13
Net debt / FCF	-0.7
Piotroski F-Score	3
Property, plant and equipment	$647,000
Shareholders' equity	$425.4M
Tangible book value	$331.5M
Tangible book value per share	$17.77
Total assets	$521.1M
Total cash	$95.3M
Total debt	$40M
Total liabilities	$95.6M
WACC	10.81%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.76
Current assets	$185.5M
Current liabilities	$95.6M
Current ratio	1.94
Inventory turnover	3.38
Net working capital	$34.5M
Quick ratio	1.58
Working capital	$89.9M
Working capital turnover	3.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-8.67%
Dividend yield	0%
Shareholder yield	-8.67%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	97.61%
10Y return CAGR	7.05%
10Y total return	97.61%
150-day SMA	$38.38
15Y price change	-38.7%
15Y return CAGR	-3.21%
15Y total return	-38.7%
1D price change	0.06%
1M price change	4.59%
1M total return	4.59%
1W price change	4.74%
1W total return	4.74%
1Y price change	70.35%
1Y return CAGR	70.41%
1Y total return	70.35%
20-day SMA	$48.07
200-day SMA	$37.02
20Y price change	-55.29%
20Y return CAGR	-3.94%
20Y total return	-55.29%
3M price change	34.77%
3M total return	34.77%
3Y price change	590.09%
3Y return CAGR	90.36%
3Y total return	590.09%
50-day SMA	$47.47
50-day SMA vs 200-day SMA	50over200
52-week high	$52.24
52-week high date	2025-11-28
52-week low	$24.95
52-week low date	2026-03-19
5Y price change	54.1%
5Y return CAGR	9.04%
5Y total return	54.1%
6M price change	65.16%
6M total return	65.16%
All-time high	$1,147.51
All-time high date	2001-01-03
All-time low	$6.40
All-time low date	2022-06-13
Average true range (ATR)	$1.65
Average volume	206.4K
Beta (1Y)	1.32
Beta (2Y)	1.92
Beta (5Y)	1.19
Change from 52-week high	-3.18%
Change from 52-week low	102.73%
Change from all-time high	-95.61%
Change from all-time low	687.34%
Change from open	0.36%
Day's gap	-0.3%
Dollar volume	$8.8M
High price	$50.95
Low price	$50.39
Monthly RSI	64.31
Open price	$50.40
Position in 52-week range	33.93%
Premarket change	-0.84%
Premarket close	$50.55
Premarket price	$50.12
Previous close	$50.55
Price vs 150-day SMA	31.29%
Price vs 20-day SMA	4.83%
Price vs 200-day SMA	36.13%
Price vs 50-day SMA	6.14%
Relative volume	0.84
RSI	61.38
Sharpe ratio	1.08
Sharpe ratio (3Y)	1.13
Sharpe ratio (5Y)	0.49
Sortino ratio	2.01
Sortino ratio (3Y)	2.04
Sortino ratio (5Y)	0.83
Volume	174.2K
Weekly RSI	65.2
YTD price change	17.65%
YTD total return	17.65%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	14.8M
Float percentage	79.44%
Shares change (QoQ)	-0.59%
Shares change (YoY)	8.67%
Shares held by insiders	1.74%
Shares held by institutions	74.76%
Shares outstanding	18.7M
Short % of float	19.24%
Short % of shares	15.29%
Short ratio	12.2 days

Deeper analysis on RIGL

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RIGL report

Is a complete RIGL research report available?

No complete published report is available for Rigel Pharmaceuticals, Inc. (RIGL) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Rigel Pharmaceuticals, Inc. (RIGL)

Price

Financial snapshot

Fair-value bridge

Latest news · RIGL

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RIGL indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RIGL

Frequently asked questions